Cardiovascular Clinical Science Foundation Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2012
NCT01584557
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Cardiovascular Clinical Science Foundation

Active Ingredients

Drugs in Phase 3 Trials (1)

tolvaptan (samsca) (1 trial)

Drugs in Phase 2 Trials (1)

cxa-10 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 3)

Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2